Jóhannes Reynisson - Eiginleikar þekkts lyfjageims
Dr. Jóhannes Reynisson heldur fyrirlesturinn "Eiginleikar þekkts lyfjageims" (The Nature of Known Drug Space) mánudaginn 11, maí kl. 12 í stofu M105.
Útdráttur / Abstract
Þekktur lyfjageimur (ÞLG) er skilgreindur sem allar sameindir notaðar sem lyf. ÞLG er hægt að nota sem viðmið við ákvarðanatöku við þróun lyfja. Þá vaknar spurning hverjir eru eiginleikar ÞLG? Við nánari athugun er ÞLG 10% nattúruefni, 29% afleiður þeirra og restin (61%) smáar lífrænar sameindir. Auk þess er möguleg stærð ÞLG áætluð sem 2.0 ×106 sameindir. Að lokum er það ljóst að happ hefur haft jákvæð áhrif á lyfjaþróun.
Known drug space (KDS) is defined as all molecules that are used in the clinic. It can be used as a metric in exploring ideas within the framework of drug discovery programmes. This begs the question what is the nature of KDS? It was found that 10% of drugs are natural products, 29% are their derivatives and the rest (61%) have a synthetic origin. Furthermore, the size of KDS is predicted to be 2.0×106 molecules. Finally, it was found that serendipity has played a crucial part in populating KDS.
Ferill / Bio
Dr. Jóhannes Reynisson lærði efnafræði við Háskóla Íslands (BSc/MSc) og Kaupmannahafnarháskóla (PhD). Því næst var hann nýdoktor við Max-Planck-Institut für Strahlenchemie. Hann vann við Institute of Cancer Research í Lundúnum og sem lektor við Nottingham Trent Háskólann. Hann er nú yfirlektor við Háskólann í Auckland, Nýja Sjálandi.
Dr. Reynisson read chemistry at the University of Iceland (BSc/MSc) and University of Copenhagen (PhD). This was followed by a post-doc at the Max-Planck-Institute for Radiation Chemistry. He worked at the Institute of Cancer Research in London as a molecular modeller and then as a lecturer at the Nottingham Trent University. He is now a Senior Lecturer in computational chemistry and molecular modelling at the School of Chemical Sciences, University of Auckland, New Zealand.
